NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.62 -1.01 (-1.22%) GOLD FUTURES
2,304.80 -52.90 (-2.24%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,961.65 -2,496.93 (-4.95%)
MannKind Corporation (MNKD)
After hours:
| Previous close | 4.2600 |
| Open | 4.2400 |
| Bid | 4.1000 x 600 |
| Ask | 4.1500 x 300 |
| Day's range | 4.1100 - 4.3100 |
| 52-week range | 3.1700 - 5.7500 |
| Volume | |
| Avg. volume | 2,899,475 |
| Market cap | 1.113B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.08 |
GlobeNewswireMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will proceed with a first-i
- GlobeNewswire
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Ph
- GlobeNewswire
MannKind Repays Certain Debt Obligations
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 millionTotal debt reduced since December 31, 2023 is approximately $41.8 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled thera
